RxDoctor Payments Data

Sanjeev Gupta, MD

Internal Medicine · Crystal Lake, ILNPI 1659471175

Payments from drug & device makers

$3,081in general payments, 2019–2025

Across 41 payments — averaging $75.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$620
  • Sanofi-aventis U.S. LLC$475
  • Novo Nordisk$423
  • AstraZeneca$382
  • GSK$282
  • Boehringer Ingelheim$202
  • plus $697 from 8 others

What the payments were for

  • Food & beverage$3,081100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,081 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$257,504
Medicare patients
374
Services billed
3,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$150,032
JardianceEmpagliflozin100$129,668
EliquisApixaban59$61,631
MounjaroTirzepatide39$52,015
FarxigaDapagliflozin Propanediol33$46,160
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$42,323
TrulicityDulaglutide24$33,360
RybelsusSemaglutide20$30,839
Breo ElliptaFluticasone/Vilanterol61$28,233
JanuviaSitagliptin Phosphate12$19,313
Bydureon BciseExenatide Microspheres12$17,157
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$15,379
XareltoRivaroxaban15$12,355
Lantus SolostarInsulin Glargine,hum.Rec.Anlog83$11,832
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$10,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$423$180,87092 claims
Boehringer IngelheimJardiance, Stiolto Respimat$202$145,047119 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$282$87,900154 claims
Lilly USA, LLCMounjaro, Trulicity$116$85,37463 claims
AstraZenecaFarxiga$382$46,16033 claims
MerckJanuvia, Janumet Xr$125$27,18629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Crystal Lake

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →